Dexamethasone Lipodisq Sterile Solution
| Code | Size | Price |
|---|
| IAX-700-107-L001 | 1 ml | £197.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
Short term: +4°C. Long term: +4°C
Documents
Further Information
Alternate Names/Synonyms:
MK-125; NSC 34521; 9I?-Fluoro-16I?-methylprednisolone; 9-Fluoro-11I,17,21-trihydroxy-16I?-methyl-pregna-1,4-diene-3,20-dione
Biological Activity:
Discoidal nano-particles can incorporate hydrophobic, poorly water-soluble compounds, such as lipids, lipoproteins and glycolipids. - Cell culture tested (human macrophage cell line) (MTT). - Recommended starting dilution: 1:200 or higher. - Optimal working concentrations depend on the applications and need to be determined. - Published procedures using Lipodisq formulations (Curcumin and IAXO TLR4 antagonists) in vivo rodent models at 3-10mg/kg. Recommended route of administration is subcutaneous (s.c.) with oral or nasal application as a possible alternative, which needs to be optimized.
CAS:
50-02-2
Concentration:
1mg/ml (0.1% w/vol)
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid, detergent-free discoidal nano-formulation made of styrene-maleic acid lipid particles (SMALP), lecithin and sterile water.
GHS Symbol:
GHS08
Handling Advice:
Keep sterile. Avoid skin and eye contact.
Hazards:
H360D
InChi:
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
InChiKey:
UREBDLICKHMUKA-CXSFZGCWSA-N
Long Description:
Chemical. CAS: 50-02-2. Formula: C22H29FO5. MW: 392.5. Dexamethasone Lipodisq Sterile Solution is a ready-to-use nano-formulated aqueous solution. Dexamethasone, developed in 1957 and granted FDA approval in 1958, is a corticosteroid structurally similar to hydrocortisone and prednisolone. Dexamethasone is used to treat conditions including: endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, and edematous and most recently COVID-19. Dexamethasone Lipodisq is based on a nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane molecules. The resulting encapsulated actives are rendered water-soluble and specialized for intra-cellular penetration/delivery via endosomal uptake mechanisms. Lipodisq solutions show a good safety profile and are suitable for in vitro and in vivo investigations.
MDL:
MFCD00064136
Molecular Formula:
C22H29FO5
Molecular Weight:
392.5
Other data:
Lipodisq™ technology is covered by one or more of the following patents owned by Malvern Cosmeceutics Limited: AU2006253886, CA2611144, CN101184473B, EP1890675, GB2426703, IN261468, JP5142898, US8623414 and WO/2021/005340A1 pending. The purchaser is licensed under those patents to use these assemblies for the purpose of research and development only, but not for the purpose of delivery of agents for clinical use to humans or veterinary use to animals for therapeutic, diagnostic or prophylactic purposes, which uses are specifically prohibited.
Package Type:
Vial
Precautions:
P280, P308+P313
Product Description:
Dexamethasone Lipodisq Sterile Solution is a ready-to-use nano-formulated aqueous solution. Dexamethasone, developed in 1957 and granted FDA approval in 1958, is a corticosteroid structurally similar to hydrocortisone and prednisolone. Dexamethasone is used to treat conditions including: endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, and edematous and most recently COVID-19. Dexamethasone Lipodisq is based on a nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane molecules. The resulting encapsulated actives are rendered water-soluble and specialized for intra-cellular penetration/delivery via endosomal uptake mechanisms. Lipodisq solutions show a good safety profile and are suitable for in vitro and in vivo investigations.
Purity:
>95% (HPLC)
Signal Word:
Warning
SMILES:
O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@]4(O)C(CO)=O)=C1
Solubility Chemicals:
Soluble in water, PBS, Tris and other physiological solutions as formulated in a proprietary, thermostable, aqueous lipid nanoparticulate formulation (Lipodisq).
Transportation:
Non-Hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 1 year after receipt when stored at +4°C.
References
Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasone: J.P. Siska, et al.; J. Clin. Invest. 131, e148225 (2021) | Dexamethasone for Severe COVID-19: How Does It Work at Cellular and Molecular Levels? T. Kino, et al.; Int. J. Mol. Sci. 22, 6764 (2021) | Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics: S. Kumar, et al.; Front. Immunol. 12, 752227 (2021) | Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19: S. Sinha, et al.; Nat. Med. 28, 201 (2022) | General References for Lipodisq™ Technology: | Responsive Hydrophobically Associating Polymers: A Review of Structure and Properties: S.R. Tonge & B.J. Tighe; Adv. Drug Deliv. Rev. 53, 109 (2001) | Detergent-free formation and physico-chemical characterization of nanosized lipidpolymer complexes: Lipodisq; M.C. Orwick, et al.; Angew. Chem. 51, 4653 (2012) | Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin: M.L. Torgersen, et al.; J. Biomed. Nanotechnol. 16, 41 (2020) | Applications of Synthetic Polymer Discoidal Lipid Nanoparticles to Biomedical Research: M. Tanaka; Chem. Pharm. Bull. 70, 507 (2022) | Mechanisms of Formation, Structure, and Dynamics of Lipoprotein Discs Stabilized by Amphiphilic Copolymers: A Comprehensive Review: P.S. Orekhov, et al.; Nanomaterials 12, 361 (2022)